NVCR
NovoCure LimitedNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.45
P/S
1.83
EV/EBITDA
-10.58
DCF Value
$-36.19
FCF Yield
-6.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.5%
Operating Margin
-23.5%
Net Margin
-20.8%
ROE
-39.1%
ROA
-16.9%
ROIC
-25.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $174.3M | $-24.5M | $-0.22 |
| FY 2025 | $655.4M | $-136.2M | $-1.22 |
| Q3 2025 | $167.2M | $-37.3M | $-0.33 |
| Q2 2025 | $158.8M | $-40.1M | $-0.36 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
JE
Exchange
NASDAQ
Beta
0.82
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.